Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Spinal Cord Injury, Traumatic Brain Injury, and Leukemia, 23475 [E8-9401]

Download as PDF Federal Register / Vol. 73, No. 84 / Wednesday, April 30, 2008 / Notices Request for Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_submission@omb.eop.gov or by fax to 202–395–6974, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Cathrine Sasek, Coordinator, Science Education Program, Office of Science Policy and Communications, National Institute on Drug Abuse, 6001 Executive Blvd, Room 5237, Bethesda, MD 20892, or call non-toll-free number (301) 443– 6071; fax (301) 443–6277; or by e-mail to csasek@nida.nih.gov. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication. Dated: April 25, 2008. Mary Affeldt, Associate Director for Management, National Institute for Drug Abuse. [FR Doc. E8–9541 Filed 4–29–08; 8:45 am] rwilkins on PROD1PC63 with NOTICES BILLING CODE 4140–01–P VerDate Aug<31>2005 17:09 Apr 29, 2008 Jkt 214001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Spinal Cord Injury, Traumatic Brain Injury, and Leukemia National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), announces that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in 1. E–073–1999/ 0–US–02, patent 6,737,511, issued May 15, 2004, entitled Receptor-Mediated Uptake of an Extracellular BCL–XL Fusion Protein Inhibits Apoptosis and 2. E–073–1999/0–US–05, patent application number 11/692,112 filed March 27, 2007, entitled ReceptorMediated Uptake of an Extracellular BCL–XL Fusion Protein Inhibits Apoptosis, to Protox Therapeutics Incorporated (Protox), having a place of business in Vancouver and Victoria, Canada. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to therapeutics for the treatment of spinal cord injury, traumatic brain injury and leukemia. DATES: Only written comments and/or license applications which are received by the National Institutes of Health on or before June 30, 2008 will be considered. ADDRESSES: Requests for copies of the patent and/or patent applications, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: John Stansberry, PhD, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–5236; Facsimile: (301) 402– 0220; E-mail: stansbej@mail.nih.gov. SUPPLEMENTARY INFORMATION: This technology could be used to minimize or prevent apoptotic damage that can be caused by neurodegenerative disorders or conditions like Alzheimer’s disease, Huntington’s disease, spinal-muscular atrophy, stroke episodes, transient ischemic neuronal injury or spinal cord injuries. Additionally, apoptotic- PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 23475 enhancing fusion proteins of the current invention could be used to inhibit cell growth and inhibit uncontrolled cellular proliferation. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: April 23, 2008. David Sadowski, Deputy Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–9401 Filed 4–29–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY [Docket No. DHS–2008–0041] National Protection and Programs Directorate; the Critical Infrastructure Partnership Advisory Council (CIPAC) Quarterly Update National Protection and Programs Directorate, DHS. ACTION: Update of CIPAC council membership. AGENCY: SUMMARY: The Department of Homeland Security (DHS) announced the establishment of the Critical Infrastructure Partnership Advisory Council (CIPAC) by notice published in the Federal Register on March 24, 2006. See 71 FR 14930. That notice identified the purpose of CIPAC as well as its membership. This notice provides (i) a brief description of the CIPAC purpose, composition, and structure; (ii) notice of the Secretary’s renewal of the CIPAC Charter; and (iii) instructions for obtaining the CIPAC membership roster and other information on the Council and its activities. FOR FURTHER INFORMATION CONTACT: Carlos Kizzee, Deputy Director, E:\FR\FM\30APN1.SGM 30APN1

Agencies

[Federal Register Volume 73, Number 84 (Wednesday, April 30, 2008)]
[Notices]
[Page 23475]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-9401]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive License: Therapeutics for the 
Treatment of Spinal Cord Injury, Traumatic Brain Injury, and Leukemia

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
Part 404.7(a)(1)(i), announces that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the inventions embodied in 1. E-073-
1999/0-US-02, patent 6,737,511, issued May 15, 2004, entitled Receptor-
Mediated Uptake of an Extracellular BCL-XL Fusion Protein Inhibits 
Apoptosis and 2. E-073-1999/0-US-05, patent application number 11/
692,112 filed March 27, 2007, entitled Receptor-Mediated Uptake of an 
Extracellular BCL-XL Fusion Protein Inhibits Apoptosis, to Protox 
Therapeutics Incorporated (Protox), having a place of business in 
Vancouver and Victoria, Canada. The patent rights in these inventions 
have been assigned to the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to therapeutics for the treatment of 
spinal cord injury, traumatic brain injury and leukemia.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before June 30, 
2008 will be considered.

ADDRESSES: Requests for copies of the patent and/or patent 
applications, inquiries, comments and other materials relating to the 
contemplated exclusive license should be directed to: John Stansberry, 
PhD, Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804; Telephone: (301) 435-5236; Facsimile: (301) 
402-0220; E-mail: stansbej@mail.nih.gov.

SUPPLEMENTARY INFORMATION: This technology could be used to minimize or 
prevent apoptotic damage that can be caused by neurodegenerative 
disorders or conditions like Alzheimer's disease, Huntington's disease, 
spinal-muscular atrophy, stroke episodes, transient ischemic neuronal 
injury or spinal cord injuries. Additionally, apoptotic-enhancing 
fusion proteins of the current invention could be used to inhibit cell 
growth and inhibit uncontrolled cellular proliferation.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establish that the grant of 
the license would not be consistent with the requirements of 35 U.S.C. 
209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 23, 2008.
David Sadowski,
Deputy Director, Division of Technology Development and Transfer, 
Office of Technology Transfer, National Institutes of Health.
 [FR Doc. E8-9401 Filed 4-29-08; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.